Related Experiment Video
Updated: Aug 24, 2026
Middle Cerebral Artery Occlusion Allowing Reperfusion via Common Carotid Artery Repair in Mice
Published on: January 23, 2019
[Biodiv Ysio stent for symptomatic stenosis of middle cerebral artery]
Wei-jian Jiang1, Bin Du, Yong-jun Wang
1Neurovascular Angioplasty Team, Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing 100050, China. jwj@2911.net
Insights
The Biodiv Ysio stent demonstrated a high technical success rate for treating symptomatic middle cerebral artery (MCA) stenosis. This endovascular approach appears safe and feasible for patients refractory to medical therapy.
Area of Science:
- Interventional Neurology
- Cerebrovascular Diseases
- Medical Device Technology
Context:
- Middle cerebral artery (MCA) stenosis poses a significant risk for ischemic stroke.
- Medical therapy is often insufficient for severe or symptomatic MCA stenosis.
- Endovascular treatment options are being explored for complex cerebrovascular lesions.
Purpose:
- To evaluate the safety and feasibility of the Biodiv Ysio stent for treating symptomatic M1 segment MCA stenosis.
- To assess the technical success rate and complication profile of this stenting procedure.
- To determine the long-term patency and clinical outcomes following stenting.
Summary:
- A study involving 43 patients with 45 M1 MCA stenoses (50-99% reduction) treated with Biodiv Ysio stent.
- Achieved a 97.8% technical success rate with a 7.0% subarachnoid hemorrhage and 2.3% mortality rate.
- Follow-up showed no stroke recurrence in 41 patients, with good patency in 6/7 stented vessels at 6 months.
Impact:
- Biodiv Ysio stenting is a safe and feasible option for symptomatic MCA M1 stenosis unresponsive to medical treatment.
- This study provides evidence supporting endovascular intervention for specific cerebrovascular conditions.
- Further research is warranted to confirm these findings in larger patient cohorts.
Objective:
To assess the safety and feasibility of Biodiv Ysio stent for patients with symptomatic M1 stenosis of middle cerebral artery (MCA).
Methods:
Forty-three patients with forty-five M1 stenoses, ranged from 50% to 99% in diameter reduction and refractory to medical therapy, were enrolled in this study between March 2002 and November 2003. The lesions were situated at M1 trunk (n = 19), M1 origin (n = 12) and M1 bifurcation (n = 14), respectively.
Results:
The technical successful rate was 97.8% (44/45) for all the lesions. The rate of complicating subarachnoid hemorrhage was 7.0% (3/43 patients) and the rate of death was 2.3%. During a follow-up of 7.0 months (median), there was no recurrence of transient ischemic attack or stroke in 41 available patients. Six-month angiographic follow-up was obtained in 6 patients (7 vessels), demonstrating good patency in 6 stenting vessels and restenosis in one vessel.
Conclusions:
Angioplasty associated with Biodiv Ysio stent appears to be a safe and feasible for the patients with symptomatic M1 stenosis of MCA, under strict control of periperformeral project. Further study is, however needed.
